Formerly | Trinity Laboratories (1959–1971) |
---|---|
Company type | Public |
ISIN | INE685A01028 |
Industry | Pharmaceuticals |
Founded | 1959 |
Founder | U. N. Mehta |
Headquarters | Ahmedabad, Gujarat, India |
Area served | Worldwide |
Key people |
|
Products | |
Revenue | ₹10,728 crore (US$1.3 billion) (FY24) [2] |
₹3,368 crore (US$400 million) (FY24) [2] | |
₹1,656 crore (US$200 million) (FY24) [2] | |
Number of employees | 12,881 (2020) [3] |
Parent | Torrent Group |
Website | www.torrentpharma.com |
Torrent Pharmaceuticals Ltd is an Indian multinational pharmaceutical company, part of the Torrent Group and headquartered in Ahmedabad. It was promoted by U. N. Mehta, initially as Trinity Laboratories Ltd, and was later renamed Torrent Pharmaceuticals Ltd.
Torrent Pharmaceuticals operates in more than 40 countries with over 2,000 product registrations globally. Torrent Pharma is active in the therapeutic areas of cardiovascular, central nervous system, gastro-intestinal, diabetology, anti-infective and pain management segments. It also has a presence in therapeutic segments of nephrology, oncology, gynecology and pediatrics. [4]
This section needs expansion. You can help by
adding to it. (May 2024) |
Torrent Pharmaceuticals was established in 1959 by U. N. Mehta as Trinity Laboratories. It was renamed as Torrent Pharmaceuticals in 1971. [5]
In 1997, Torrent Pharma and Sanofi established a 50:50 joint venture called Sanofi Torrent for selling Torrent Pharma's products. [6] Torrent exited the joint venture by selling its stake to Sanofi in 2002. [7]
In 2005, Torrent Pharmaceuticals acquired Heumann Pharma Generics GmbH, a Pfizer company based in Germany. [8]
In 2013, Torrent Pharma acquired the India formulations business of Elder Pharmaceuticals for ₹2,004 crore (US$341.99 million). [9]
In 2017, Torrent Pharma acquired the domestic business of Unichem Laboratories for ₹3,600 crore (US$552.81 million). [10]
In 2022, the company acquired skincare manufacturer Curatio Healthcare for ₹2,000 crore (US$254.44 million). [11]
It has 7 fully owned subsidiaries:
The company's key areas are Formulations, API, Drug Discovery, Marketing and Sales of Drugs. Its operations locations are:
In 2018, Torrent Pharmaceuticals recalled tablets containing valsartan [14] [15] and losartan [16] due to the detection of N-nitrosodimethylamine (NDMA) and N-nitrosodiethylamine (NDEA) respectively which are probable human carcinogens.
In September 2019, the FDA issued notice of a sixth product recall of losartan by Torrent Pharmaceuticals when certain batches of losartan contained the contaminant, N-methylnitrosobutyric acid (NMBA), above acceptable daily intake levels determined by the FDA. [17]
Torrent Pharmaceuticals Limited is voluntarily recalling ALL LOTS within expiry of Valsartan/Amlodipine/HCTZ, Valsartan/Amlodipine and Valsartan tablets to the consumer level due to the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) manufactured by Zhejiang Huahai Pharmaceuticals. The impurity detected in the API is N-nitrosodimethylamine (NDMA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen as per International Agency for Research on Cancer (IARC) classification.
Torrent Pharmaceuticals Limited is voluntarily recalling 2 lots of Losartan potassium tablets, USP to the consumer level due to the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) manufactured by Hetero Labs Limited. The impurity detected in the API is N-nitrosodiethylamine (NDEA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen as per International Agency for Research on Cancer (IARC) classification.